Oorsprong van het eerstegraads netwerk van Debra Manning
| Entiteit | Type entiteit | Industrie | |
|---|---|---|---|
| Public Company | Pharmaceuticals: Major | 22 |
Grafiek van bedrijven verbonden in de tweede graad
Connectie in verschillende bedrijven
Bedrijven verbonden met Debra Manning via zijn persoonlijke netwerk
| Onderneming | Sector | Gelieerde personen | Hoofdpost |
|---|---|---|---|
| DANAHER CORPORATION | Medical Specialties | Chief Tech/Sci/R&D Officer | |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Biotechnology | Chief Tech/Sci/R&D Officer | |
| TG THERAPEUTICS, INC. | Pharmaceuticals: Major | Founder Chief Executive Officer Director/Board Member | |
| NATIONAL HOLDINGS CORPORATION | Investment Banks/Brokers | Chairman Director/Board Member | |
F. Hoffmann-La Roche Ltd.
 F. Hoffmann-La Roche Ltd. Pharmaceuticals: MajorHealth Technology F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Carnegie Mellon University
 Carnegie Mellon University Other Consumer ServicesConsumer Services Carnegie Mellon University is an American school that operates as a college or university. It is located in Pittsburgh, Pennsylvania. | College/University | Undergraduate Degree | |
| KERYX BIOPHARMACEUTICALS | Pharmaceuticals: Major | Founder Chief Executive Officer | |
| BRAINSTORM CELL THERAPEUTICS INC. | Biotechnology | Chief Tech/Sci/R&D Officer | |
| FORTRESS BIOTECH, INC. | Pharmaceuticals: Major | Chief Executive Officer Director/Board Member Comptroller/Controller/Auditor | |
Arvinas Operations, Inc.
 Arvinas Operations, Inc. BiotechnologyHealth Technology Arvinas Operations, Inc. develops novel therapeutics for the treatment of cancer, pro-inflammatory, autoimmune and rare diseases. It offers proteolysis-targeting chimera PROTAC-based drugs that induce protein degradation to target and eliminate disease-causing proteins from the body. The company was founded by Craig M. Crews in July 2013 and is headquartered in New Haven, CT. | Biotechnology | Chief Executive Officer | |
| The Johns Hopkins University | College/University | Undergraduate Degree | |
| Monmouth University | College/University | Graduate Degree | |
| Tulane University (Louisiana) | College/University | Undergraduate Degree | |
| Princeton University | College/University | Undergraduate Degree | |
| Roosevelt University | College/University | Masters Business Admin | |
| University of Florida | College/University | Undergraduate Degree | |
| University of Maryland | College/University | Graduate Degree | |
| Yeshiva University | College/University | Undergraduate Degree Undergraduate Degree | |
Memorial Sloan Kettering Cancer Center
 Memorial Sloan Kettering Cancer Center Hospital/Nursing ManagementHealth Services Memorial Sloan-Kettering Cancer Center operates as a private cancer center. It offers cancer care services to adult; and child and teen patients. Its services include risk assessment and screening; diagnosis and treatment; clinical trials; patient and caregiver education; and pediatric clinical trials. The company was founded by John J. Astor and Charlotte Astor in 1884 and is headquartered in New York, NY. | Hospital/Nursing Management | Corporate Officer/Principal | |
Novartis Pharmaceuticals Corp.
 Novartis Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Novartis Pharmaceuticals Corp. develops, manufactures, and markets prescription drugs. It manufactures and markets prescription drugs used to treat a number of diseases and conditions including cardiovascular, dermatological, central nervous system, bone disease, cancer, organ transplantation, psychiatry, infectious disease, and respiratory. The company was founded in 1996 and is headquartered in East Hanover, NJ. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
| American Friends of Shalva, Inc. | Corporate Officer/Principal | ||
Opus Point Partners Management LLC
 Opus Point Partners Management LLC Investment ManagersFinance Opus Point Partners Management LLC (OPPM) is a hedge fund manager headquartered in New York City. The firm was founded by Lindsay Rosenwald and Michael Weiss in 2009. They are owned by Opus Point Partners LLC, which is a subsidiary of Weiss & Co. LLC. OPPM manages investments that are dedicated to healthcare and life science. | Investment Managers | Chief Executive Officer Founder | |
| Weill Cornell Medical College | College/University | Corporate Officer/Principal | |
| Albert Einstein College of Medicine, Inc. | College/University | Doctorate Degree | |
| Columbia Law School | College/University | Graduate Degree Graduate Degree | |
| KITE PHARMA INC | Biotechnology | Corporate Officer/Principal | |
| American Brachytherapy Society | President | ||
Amerigen Pharmaceuticals Ltd.
 Amerigen Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Amerigen Pharmaceuticals Ltd. engages in the development, manufacturing, and sale of generic pharmaceutical products. The company was founded in 2007 and is headquartered in Lyndhurst, NJ. | Pharmaceuticals: Major | Corporate Officer/Principal | |
| Yale School of Medicine | College/University | Doctorate Degree | |
| Carmel Academy, Inc. | College/University | Director/Board Member | |
| Lsu Medical School | College/University | Doctorate Degree | |
| ORIGO ACQUISITION CORP | Financial Conglomerates | Chief Executive Officer Chairman Director/Board Member Director/Board Member | |
| CHECKPOINT THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member Chairman Director/Board Member Investor Relations Contact | |
| AVENUE THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member Investor Relations Contact | |
| LEGEND BIOTECH CORPORATION | Pharmaceuticals: Major | Corporate Officer/Principal | |
| AVROBIO, INC. | Biotechnology | Corporate Officer/Principal | |
Helocyte, Inc.
 Helocyte, Inc. Miscellaneous Commercial ServicesCommercial Services Helocyte, Inc. engages in the development and commercialization of immunotherapies for the prevention and treatment of cytomegalovirus or CMV (cancer and infectious disease). It focuses on developing PepVax, a HLA-restricted single antigen peptide vaccine for controlling CMV in allogeneic hematopoietic stem cell transplant recipients and Triplex. The company was founded by Donald J. Diamond in 2015 and is headquartered in New York, NY. | Miscellaneous Commercial Services | Founder Director/Board Member | |
| CONVATEC GROUP PLC | Medical Specialties | Corporate Officer/Principal | |
Cyprium Therapeutics, Inc.
 Cyprium Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Fortress Biotech, Inc., Cyprium Therapeutics, Inc. is an American New York-based company focused on developing novel therapies for the treatment of Menkes disease and related copper metabolism disorders. The company was granted FDA breakthrough therapy, fast track, and rare pediatric disease designations, as well as FDA orphan drug designation for both Cutx-101 and AAV-ATP7A. The European Medicines Agency also granted orphan drug designation to Cyprium. In March 2017, Cyprium entered into a cooperative research and development agreement with the Eunice Kennedy Shriver National Institute of Child Health and Human Development to advance the clinical development of Cutx-101 for the treatment of Menkes disease. In 2023, Cyprium completed the transfer of its proprietary rights and assigned its FDA documents pertaining to Cutx-101 to Sentynl Therapeutics, Inc. Cyprium and NICHD also previously entered into a worldwide, exclusive license agreement to develop and commercialize AAV-ATP7A gene therapy, which is currently in pre-clinical development. The company was founded in 2017 by Michael Sean Weiss, Lindsay Allan Rosenwald, and Lung S. Yam, who has been the CEO since then. | Miscellaneous Commercial Services | Founder Founder | |
| Cellvation, Inc. | Chairman Director/Board Member | ||
| JOURNEY MEDICAL CORPORATION | Pharmaceuticals: Major | Chairman Director/Board Member Investor Relations Contact | |
| VOR BIOPHARMA INC. | Biotechnology | Chief Tech/Sci/R&D Officer | |
Caelum Biosciences, Inc.
 Caelum Biosciences, Inc. BiotechnologyHealth Technology Caelum Biosciences, Inc. operates as a clinical-stage biotechnology company developing treatments for rare and life-threatening diseases. The company was founded in January 2017 and is headquartered in New York, NY. | Biotechnology | Director/Board Member Director/Board Member | |
RA Capital Management LP (Private Equity)
 RA Capital Management LP (Private Equity) Investment ManagersFinance RA Capital Management LP (Private Equity) (RA Capital) is a private equity & venture capital subsidiary of RA Capital Management LP founded by Peter Kolchinsky in 2004. The firm is headquartered in Boston, MA. | Investment Managers | Consultant / Advisor | |
On Demand Pharmaceuticals, Inc.
 On Demand Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology On Demand Pharmaceuticals, Inc. is an innovative technology company that is transforming the way medicines are made. On Demand Pharmaceuticals is based in Richmond, VA and was founded by Shiu Fei Ling. The private company's breakthrough manufacturing technology platform, the Pharmacy on Demand (POD), allows for the production of medicines on demand, wherever and whenever they are needed. The company's mission is to provide an adequate, safe, and reliable supply of medicines to every community worldwide. | Pharmaceuticals: Major | Director of Finance/CFO | |
Baergic Bio, Inc.
 Baergic Bio, Inc. Pharmaceuticals: MajorHealth Technology Baergic Bio, Inc. develops therapeutic drugs for the treatment of central nervous system disorders. It offers oncology, rare diseases, and gene therapy. The company is headquartered in New York, NY. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Aprinoia Therapeutics, Inc. /US/
 Aprinoia Therapeutics, Inc. /US/ BiotechnologyHealth Technology Aprinoia Therapeutics, Inc. operates as a global clinical-stage biopharmaceutical company. It develops imaging diagnostic tools, targeted therapy drugs, and other products. The company was founded in 2015 and is headquartered in Cambridge, MA. | Biotechnology | Director of Finance/CFO | |
| The Bayit Association | Founder | ||
| Boston University School of Medicine | College/University | Doctorate Degree |
Statistieken
Internationaal
| Verenigde Staten | 47 |
| Kaaimaneilanden | 3 |
| Zwitserland | 2 |
| Verenigd Koninkrijk | 2 |
Sectoraal
| Health Technology | 23 |
| Consumer Services | 17 |
| Finance | 6 |
| Commercial Services | 3 |
| Health Services | 2 |
Operationeel
| Director/Board Member | 43 |
| Corporate Officer/Principal | 32 |
| Chairman | 23 |
| Director of Finance/CFO | 22 |
| Undergraduate Degree | 16 |
Sterkste connecties
| Insiders | |
|---|---|
| Michael Weiss | 25 |
| Lindsay Rosenwald | 23 |
| Neil Herskowitz | 22 |
| Eliot Lurier | 13 |
| Adam Chill | 11 |
| Sadik Kassim | 8 |
| Brian Achenbach | 8 |
| James Murphy | 8 |
| Susan E. Ward | 7 |
| Manuel Litchman | 6 |
| Michael Zelefsky | 6 |
| Martina A. Sersch | 5 |
| Lynn E. Bayless | 5 |
| Greg Furrow | 5 |
| Albert Paszek | 5 |
- Beurs
- Insiders
- Debra Manning
- Bedrijfsconnecties